Mazdutide plus a hormonal IUD for early uterine lining cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new treatment for very early endometrial cancer or a precancerous condition, aiming to help you avoid a hysterectomy and keep the chance of having children. It combines a medication (mazdutide) that helps with weight and hormone problems with a hormonal intrauterine device (LNG-IUS) to treat the lining of the womb.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 45 and you want to keep your ability to have a baby.
- You have a confirmed diagnosis of atypical endometrial hyperplasia or a very early-stage, low-grade endometrial cancer that has not spread into the muscle of the womb.
- Your tumor is estrogen receptor positive, and for cancer, it is not the aggressive p53-abnormal type.
- You are overweight or obese (BMI 28 or higher, or BMI 24 or higher with a weight-related condition like high blood pressure or diabetes).
- You have not had previous hormone treatment for this condition and are not currently pregnant or breastfeeding.
- You agree to close follow-up and accept the risks of delaying more radical surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This study compares two approaches for women with obesity and early-stage endometrial cancer: having surgery right away versus going through a special weight-loss and health-optimization program before surgery. The goal is to see if preparing the body before surgery improves outcomes.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.